NO953329L - Recombinant viruses and their use in gene therapy for the treatment of eye diseases - Google Patents

Recombinant viruses and their use in gene therapy for the treatment of eye diseases

Info

Publication number
NO953329L
NO953329L NO953329A NO953329A NO953329L NO 953329 L NO953329 L NO 953329L NO 953329 A NO953329 A NO 953329A NO 953329 A NO953329 A NO 953329A NO 953329 L NO953329 L NO 953329L
Authority
NO
Norway
Prior art keywords
eye diseases
treatment
gene therapy
recombinant viruses
diseases
Prior art date
Application number
NO953329A
Other languages
Norwegian (no)
Other versions
NO319571B1 (en
NO953329D0 (en
Inventor
Pascale Briand
Michel Perricaudet
Original Assignee
Rhone Poulenc Rorer Sa
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa, Inst Nat Sante Rech Med filed Critical Rhone Poulenc Rorer Sa
Publication of NO953329L publication Critical patent/NO953329L/en
Publication of NO953329D0 publication Critical patent/NO953329D0/en
Publication of NO319571B1 publication Critical patent/NO319571B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The use of defective recombinant adenoviruses containing an inserted gene for preparing a pharmaceutical useful for treating eye diseases is disclosed.
NO19953329A 1993-03-03 1995-08-24 Use of a defective, recombinant adenovirus. NO319571B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9302438A FR2702152B1 (en) 1993-03-03 1993-03-03 Recombinant viruses and their use in gene therapy.
PCT/FR1994/000220 WO1994020146A1 (en) 1993-03-03 1994-02-28 Recombinant adenoviruses and use thereof in gene therapy for treating eye diseases

Publications (3)

Publication Number Publication Date
NO953329L true NO953329L (en) 1995-08-24
NO953329D0 NO953329D0 (en) 1995-08-24
NO319571B1 NO319571B1 (en) 2005-08-29

Family

ID=9444602

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19953329A NO319571B1 (en) 1993-03-03 1995-08-24 Use of a defective, recombinant adenovirus.

Country Status (15)

Country Link
EP (1) EP0687184B1 (en)
JP (1) JP3835809B2 (en)
AT (1) ATE220923T1 (en)
AU (1) AU693782B2 (en)
CA (1) CA2154355A1 (en)
DE (1) DE69431046T2 (en)
DK (1) DK0687184T3 (en)
ES (1) ES2181710T3 (en)
FR (1) FR2702152B1 (en)
HU (1) HU218900B (en)
NO (1) NO319571B1 (en)
NZ (1) NZ262135A (en)
PT (1) PT687184E (en)
WO (1) WO1994020146A1 (en)
ZA (1) ZA941426B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792751A (en) * 1992-04-13 1998-08-11 Baylor College Of Medicine Tranformation of cells associated with fluid spaces
FR2717823B1 (en) * 1994-03-23 1996-04-26 Rhone Poulenc Rorer Sa Recombinant viruses, preparation and use in gene therapy.
IL113052A0 (en) * 1994-03-23 1995-06-29 Rhone Poulenc Rorer Sa Recombinant viruses, their preparation and their use in gene therapy
FR2726575B1 (en) * 1994-11-09 1996-12-20 Rhone Poulenc Rorer Sa RECOMBINANT VIRUSES, PREPARATION AND USE IN GENE THERAPY
FR2717824B1 (en) 1994-03-25 1996-04-26 Rhone Poulenc Rorer Sa Recombinant viruses, preparation and use in gene therapy.
FR2718150B1 (en) 1994-03-29 1996-04-26 Rhone Poulenc Rorer Sa Recombinant viruses, preparation and use in gene therapy.
US5827702A (en) 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
US6107027A (en) * 1994-12-14 2000-08-22 University Of Washington Ribozymes for treating hepatitis C
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
US6489305B1 (en) 1998-05-08 2002-12-03 Canji, Inc. Methods and compositions for the treatment of ocular diseases
ATE303820T1 (en) * 1999-12-30 2005-09-15 Aventis Pharma Sa USE OF A VECTOR ENCODING AN ANTI-ANGIogenic FACTOR FOR THE TREATMENT OF CORNEA VASCULARIZATION
FR2803207B1 (en) * 1999-12-30 2004-04-30 Aventis Pharma Sa USE OF A VECTOR COMPRISING A NUCLEIC ACID ENCODING AN ANTI-ANGIOGENIC FACTOR FOR THE TREATMENT OF CORNEAL NEOVASCULARIZATIONS
US6821775B1 (en) 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
CN101507822B (en) 2003-11-24 2012-06-06 坎吉有限公司 Reduction of dermal scarring
EP1804835B9 (en) 2004-09-13 2010-09-29 Genzyme Corporation Multimeric constructs
SI2601214T1 (en) 2010-08-06 2018-03-30 Genzyme Corporation Vegf antagonist compositions and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990002551A2 (en) * 1988-09-13 1990-03-22 Biosource Genetics Corporation Prophylaxis and treatment of nervous system diseases with melanin
JPH06506599A (en) * 1991-04-05 1994-07-28 エディソン　アニマル　バイオテクノロジー　センター，オハイオ　ユニバーシティー Inhibition of retroviruses by antisense nucleic acids complementary to packaging sequences

Also Published As

Publication number Publication date
NO319571B1 (en) 2005-08-29
NZ262135A (en) 2000-12-22
DE69431046D1 (en) 2002-08-29
AU6144494A (en) 1994-09-26
EP0687184B1 (en) 2002-07-24
ATE220923T1 (en) 2002-08-15
HU9502573D0 (en) 1995-10-30
FR2702152A1 (en) 1994-09-09
CA2154355A1 (en) 1994-09-15
DK0687184T3 (en) 2002-10-28
ZA941426B (en) 1994-10-04
EP0687184A1 (en) 1995-12-20
HU218900B (en) 2000-12-28
HUT73215A (en) 1996-06-28
NO953329D0 (en) 1995-08-24
FR2702152B1 (en) 1995-05-24
AU693782B2 (en) 1998-07-09
WO1994020146A1 (en) 1994-09-15
JP3835809B2 (en) 2006-10-18
PT687184E (en) 2002-12-31
DE69431046T2 (en) 2003-02-13
ES2181710T3 (en) 2003-03-01
JPH08509208A (en) 1996-10-01

Similar Documents

Publication Publication Date Title
NO953329D0 (en) Recombinant viruses and their use in gene therapy for the treatment of eye diseases
FR2705361B1 (en) Viral vectors and use in gene therapy.
ATE255128T1 (en) PEPTIDE-IMMITTING SUBSTANCES IN CANCER THERAPY
AU586860B2 (en) Therapeutical application of phosphonylmethoxyalkyl adenines
ATE254926T1 (en) USE OF A CONSENSUS INTERFERON TO REDUCE ADVERSE EFFECTS IN THE INTERFERON TREATMENT OF VIRAL HEPATITES.
ATE380548T1 (en) USE OF P53 INHIBITORS FOR THE TREATMENT OF ADVERSE SYMPTOMS OF CANCER THERAPY
ATE304058T1 (en) RECOMBINANT MVA VIRUSES AND THEIR USE
DK0668763T3 (en) Use of Phenserin in the manufacture of drugs for the treatment of cognitive disorders
NO883896L (en) PROCEDURE FOR PREPARING CYTKINERMINED HUMAN IMMUNGLOBULIN CONJUGATES.
DE3877529D1 (en) MANUFACTURE OF HIGHLY-LOST HUMAN FACTOR IX AND OTHER PLASMA PROTEIN CONCENTRATE AND THEIR THERAPEUTIC USE.
DK19488A (en) RADIATION SYSTEM FOR USE IN MEDICAL TREATMENT OF NOSE AND NECK PASSAGES
DE69629570D1 (en) 3'UTR OF THE HUMAN PROHIBITIN GENE
Dhillon et al. Local anaesthetic and vasoconstrictor agents used in ENT
Dhillon et al. Photodynamic therapy
MX9706569A (en) Recombinant viruses expressing lecithin-cholesterol acyltransferase, and uses thereof in gene therapy.